---
title: "BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286776398.md"
description: "BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News"
datetime: "2026-05-18T05:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286776398.md)
  - [en](https://longbridge.com/en/news/286776398.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286776398.md)
---

# BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | BMRN Stock News

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness](https://longbridge.com/en/news/286895616.md)
- [BioMarin's genetic disease therapy shows mixed results in late-stage study](https://longbridge.com/en/news/286778854.md)
- [Project helps turn around lives of special needs children and their parents](https://longbridge.com/en/news/286424988.md)
- [Kids digital safety concerns collide with prediction market debate](https://longbridge.com/en/news/286901836.md)
- [Educare Network Convenes National Leaders in Tulsa to Reimagine the Future of Early Childhood Education](https://longbridge.com/en/news/286602887.md)